Quick Takeaways: Why It Matters? This partnership is designed to scale Rebound High Performance PRP across the US veterinary market by combining epiq’s distribution reach with Vetirus’s product and regulatory credentials, removing a key barrier to adoption-access to e...
Quick Takeaways Why It Matters? VMD Sciences is positioning itself as a supply-chain backup for large-animal practice, which matters because drug shortages can quickly disrupt equine colic care and other urgent treatments. The market implication is that it can win relevan...
Quick Takeaways Why It Matters? This deal gives Viromed a faster route to commercialize PulmoPlas in veterinary respiratory care, starting with horses, while NEBU-TEC gets exclusive global distribution rights in that segment. The biggest market upside is in ...
Quick Takeaways: Why It Matters? The strong equine proof‑of‑concept data, clean safety profile, and upcoming human knee OA feasibility study collectively de‑risk Hydrocelin’s translational path, increasing its attractiveness as a first‑in‑class, potentially disease‑mo...
Quick Takeaways: Why It Matters? The VievePharm deal gives Zenex a certified Western European manufacturing and sales base plus advanced bolus technology, accelerating its shift from an India‑focused player to a global naturals-led animal health company alig...
Quick Takeaways Why It Matters? AgmaVet For Horses gives vets and owners a non-NSAID, nutraceutical option for managing lameness and mobility, which may appeal where long-term drug side effects are a concern. By targeting both nerve function and joint healt...
Quick Takeaways: Why It Matters? The recall may temporarily weaken confidence in Neogen’s veterinary portfolio and open space for rival hyaluronate or wound-care products. It also underscores regulatory and safety scrutiny around off-label use, likely prompting v...
